Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Saved in:
| Title: | Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors. |
|---|---|
| Authors: | Tsimberidou AM; Department of Investigational Cancer Therapeutics, Katherine Russell Dixie Distinguished Endowed Professor, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. atsimber@mdanderson.org., Grothey A; Gastrointestinal Cancer Research at West Cancer Center and Research Institute, Germantown, TN, USA., Sigal D; Scripps Clinic and Scripps Cancer Center, La Jolla, CA, USA., Lenz HJ; Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Hochster HS; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Chao Y; Taipei Veterans General Hospital, Taipei, Taiwan., Bai LY; China Medical University Hospital, Taichung City, Taiwan., Yen CL; National Cheng Kung University Hospital, Tainan, Taiwan., Xu D; OBI Pharma USA, Inc, San Diego, CA, USA., Saville MW; OBI Pharma USA, Inc, San Diego, CA, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Dec; Vol. 94 (6), pp. 787-798. Date of Electronic Publication: 2024 Sep 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-024-04714-z |
